Company news
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) news
Phathom Pharmaceuticals, Inc. news releases on 6ix. Latest, Sep 29, 2026: Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study…
Press releases & updates
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD
September 29, 2026
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD
September 28, 2026
Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
July 30, 2026
Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026
July 20, 2026
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
June 23, 2026
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
May 20, 2026
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting
May 1, 2026
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
April 30, 2026
Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026
April 20, 2026
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
February 25, 2026
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026
February 17, 2026
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026
February 4, 2026
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
January 7, 2026
Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
January 7, 2026
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants
January 6, 2026
Shaya Prager Announces Opal Holdings Leasing Activity of 250,000 Square Feet Across Portfolio in 2025
January 6, 2026
Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA in Eosinophilic Esophagitis
November 5, 2025
Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
November 3, 2025
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
November 2, 2025
Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
October 29, 2025
Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease
October 24, 2025
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting
October 22, 2025
Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025
October 19, 2025
Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer
October 5, 2025
Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing
August 19, 2025
Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 6, 2025
Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025
July 27, 2025
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary
June 22, 2025
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 22, 2025
Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032
June 15, 2025
Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032
June 5, 2025
Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
April 30, 2025
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting
April 27, 2025
Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025
April 22, 2025
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors
April 15, 2025
Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
April 2, 2025
Phathom Pharmaceuticals Announces Leadership Succession
March 31, 2025
Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)
March 30, 2025
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 5, 2025
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025
February 23, 2025
Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference
January 28, 2025
Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets
December 10, 2024
Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 6, 2024
Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024
October 27, 2024
Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting
October 26, 2024
Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants
August 18, 2024
Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
August 7, 2024
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients
July 29, 2024
Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024
July 28, 2024
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults
July 17, 2024